Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by PULLAR, T.
Right arrow Articles by FEELY, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by PULLAR, T.
Right arrow Articles by FEELY, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1990 British Society for Rheumatology

other

WHAT DO PATIENTS AND RHEUMATOLOGISTS REGARD AS AN ‘ACCEPTABLE’ RISK IN THE TREATMENT OF RHEUMATIC DISEASE?

T. PULLAR, V. WRIGHT and M. FEELY

Clinical Pharmacology and Rheumatism Research Units, University Department of Medicine, The General Infirmary Leeds

Correspondence to: Correspondence to Dr T. Pullar, University Department of Medicine, Martin Wing, The General Infirmary, Leeds LS1 3EX

A questionnaire designed to ascertain the risk of adverse effects which patients with rheumatic conditions would accept for a particular therapeutic outcome was administered to 50 patients. The same questionnaire together with 'potted' histories of five of the patients was sent to 10 consultant rheumatologists. The willingness of both patients and doctors to risk side-effects varied with both the severity of the side-effect and the potential therapeutic benefit. Doctors were more willing than patients to risk death or serious disability (Wilcoxon, P≤0.01) for a particular expected benefit. Doctors were also more willing to risk side-effects in treating seropositive rheumatoid arthritis than in treating non-articular rheumatism. No correlation was seen for patients between acceptable risk and diagnosis, pain or smoking habits. The risks which both groups stated they were willing to accept were less than those apparently associated with antirheumatic therapy

The results disagreed markedly with those of a previous study, demonstrating the importance of the methods used in this type of work

KEY WORDS: Therapy, Benefits, Hazards, Toxicity, Arthritis, Death


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
L Fraenkel, S T Bogardus, J Concato, D T Felson, and D R Wittink
Patient preferences for treatment of rheumatoid arthritis
Ann Rheum Dis, November 1, 2004; 63(11): 1372 - 1378.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
L Fraenkel, S T Bogardus Jr, and D R Wittink
Risk-attitude and patient treatment preferences
Lupus, May 1, 2003; 12(5): 370 - 376.
[Abstract] [PDF]

Home page
 Rheumatology (Oxford)Home page
L. Fraenkel, S. Bogardus, J. Concato, and D. Felson
Unwillingness of rheumatoid arthritis patients to risk adverse effects
Rheumatology, March 1, 2002; 41(3): 253 - 261.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
M. Ho and T. Pullar
Risk taking in patients with rheumatoid arthritis
Rheumatology, June 1, 2000; 39(6): 680 - 680.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
J. A. Snowden and P. M. Brooks
Reply
Rheumatology, June 1, 2000; 39(6): 681 - 682.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.